ORIGINAL RESEARCH ARTICLE Involvement of PARP-1 Val762Ala Polymorphism in the Onset of Cervical Cancer in Caucasian Women

The Author(s) 2013. This article is published with open access at Springerlink.com Background and Objective Data on the Val762Ala (rs1136410) polymorphism in the poly(adenosine diphos-phate [ADP]-ribose) polymerase 1 (PARP-1) gene as a risk factor for various types of cancers in different ethnicities are inconsistent. We studied this association in a Caucasian population. Methods Using high-resolution melting curve analysis (HRM), we studied the distribution of the PARP-1 Val762Ala polymorphism in patients with cervical cancer (n = 446) and in controls (n = 491). Results Logistic regression analysis adjusting for age, pregnancy, oral contraceptive use, tobacco smoking, and menopausal status demonstrated that the PARP-1 Val762Ala polymorphism was associated with an increased risk of cervical cancer. The adjusted odds ratio (OR) for patients with the Ala/Val genotype versus the Val/Val geno-type was 1.381 (95 % CI = 1.025–1.859, p = 0.033), and the adjusted OR for the Ala/Ala or Ala/Val genotype versus the Val/Val genotype was 1.403 (95 % CI = 1.057–1.863, p = 0.019). The p value from the chi-square test of the trend observed for the PARP-1 Val762Ala polymorphism was sta-tistically significant (ptrend = 0.0123). Stratified analyses of the PARP-1 Val762Ala genotype distribution and cervical cancer risk showed that the age-adjusted OR of Ala/Ala or Ala/Val vs Val/Val for pregnancy was 1.388 (95 % CI = 1.027–1.877, p = 0.0328), 1.773 (95 % CI = 1.145–2.745, p = 0.0100) for contraceptive use, and 1.604 (95 % CI = 1.132–2.272, p = 0.0077) for postmenopausal women. The age-adjusted OR of Ala/Val vs Val/Val for contraceptive use was 1.769 (95 % CI = 1.114–2.809, p = 0.0154) and for postmenopausal women was 1.577 (95 % CI = 1.094–2.272, p = 0.0143). Conclusion Our studies suggest that the PARP-1 Val762Ala polymorphism may be a genetic risk factor for cervical cancer.